Ongoing market analysis

Digital Health Insights

Current funding analysis, market commentary, and evidence-led perspectives, supported by a searchable record of earlier research.

Topic
Region

Showing 18 of 222 insights

Seven things to stop funding before your 2027 digital health budget is signed
Digital Health FundingInvestment Trends

Seven Things to Stop Funding Before Your 2027 Budget Is Signed

Early-stage digital health rounds fell 63% since 2022. Seven things to stop funding before your 2027 digital health budget is signed.

Read insight
Blog 2027-Budget-Part-2-Build-Buy-or-Partner_title image
FundingPartnerships

Build, Buy or Partner: How to Spend a 2027 Digital Health Budget

The AI label now carries a 16% funding discount and acquired ventures average 10.7 years old. How to choose between building, buying and partnering in 2027.

Read insight
Title_Q4 Planning Manual_Part 1.png
Digital Health FundingInvestment Trends

The Ten-Week Window: A Q4 Planning Guide for Your 2027 Digital Health Budget

Most 2027 innovation budgets are written in the next ten weeks. Part one of Galen Growth’s Q4 planning guide: the market you are budgeting into

Read insight
Title Image_OpenAI Epic
BlogGlobal

Read-Only Is the Whole Story: OpenAI's Epic Integration and the Clinical Reasoning Layer, September 2026

OpenAI's Epic integration is read-only — no notes, no orders, no codes. Epic, Abridge and Ambience shipped chart reasoning first, and $1.32B backed them in 2025.SEO key phrase: OpenAI Epic integration

Read insight
Title_Pharma DH partnerships
PartnershipsPartnerships

Pharma's Digital Health Partnerships: The Asset Investors Don't See

Pharma holds 1,707 Digital Health partnerships across 13 portfolios — a measurable asset investors ignore. Novartis converts 31% to evidence grade; Bayer 18%.

Read insight
PSP Title Image_Galen Growth Blog 25 Aug
BlogGlobal

The Operating System Around the Drug: Patient Support Programmes in 2026

281 ventures, US$5.9bn raised, 628 pharma partnerships: patient support programmes are becoming treatment infrastructure. Galen Growth, 2026.

Read insight
Title Image_HingeHealth_Cylinder
BlogPartnerships

Why Hinge Health Paid $105 Million for a Company Worth Just $8 Million in Revenue

Hinge Health paid $105M for Cylinder Health, but the deal adds just $7–8M in 2026 revenue — Galen Growth's analysis of the platform-building logic behind it.

Read insight
Title Image_Digital-Health-Funding-Clinical-Evidence-2026
FundingDigital Health Funding

Digital Health Funding 2026: Ventures with Strong Clinical Evidence Raise 3.5x More

Ventures with strong clinical evidence raised 3.5x more in 2026 YTD ($112.9M vs $24.3M/round) — Galen Growth digital health funding analysis.

Read insight
Title-Image_Rules-of-Investing
FundingDigital Health Funding

Digital Health Investment Trends in H1 2026: 5 New Rules of Healthcare Innovation Venture Capital

Deal volume fell 63% in H1 2026, yet capital held at $16.6B. Galen Growth's H1 2026 Key Trends analysis reveals the 5 new rules reshaping digital health VC.

Read insight
Titel Image_Healthcare Infrastructure
Point of ViewFunding

H1 2026 Healthcare Trends: Health Systems Are Buying Infrastructure, Not Apps

Health-system partnerships with infrastructure ventures rose to 22.8% in H1 2026 from 18.8% in 2022, Galen Growth's H1 2026 data show.

Read insight
H1-Blog_Strategic-Buyer-Acquisitions_Title-Image
FundingDigital Health Funding

The Return of the Strategic Buyer: M&A Captured 98% of Digital Health Exits in H1 2026

M&A captured 97.6% of digital health exits in H1 2026 as IPOs fell to one listing. Galen Growth's H1 2026 exit analysis, powered by HealthTech Alpha.

Read insight
H1 Partnerships Title image
FundingPartnerships

H1 2026 Digital Health Trends: Why Partnerships Matter More Than Funding

Partnerships fell 20% vs a 37% funding deal decline in H1 2026. Galen Growth’s definitive read on why partnerships now signal digital health demand.

Read insight
H1 2026 Digital Health Funding Image
FundingDigital Health Funding

Global funding held broadly steady at $22.6B — H1 2026 data shows capital concentrating in fewer, larger, more scrutinised bets.

Global digital health funding held steady at $22.6B in H1 2026, but deal count fell 38% to 608. Galen Growth's definitive analysis of the maturity era.

Read insight
Digital_Health_Market_Exit_Trends
FundingDigital Health Funding

Digital Health Exits in 2026: M&A Dominance, Longer Hold Periods, and Strategic Consolidation

95% of 2025–2026 digital health exits were M&A. Galen Growth analysis of exit routes, hold periods, and capital concentration for 2026.

Read insight
The_Q3_Intelligence_Window_Strategy
Point of ViewGlobal

The Q3 Intelligence Window: Why Alpha Briefs Matter Before the Q4 Push

Q3 offers a 12-week window to turn healthcare innovation noise into Q4-ready decisions with Galen Growth Alpha Briefs.

Read insight
HealthTech Alpha data shows Europe’s startup problem is not formation. It is late-stage capital density and ownership retention
Point of ViewFunding

The €5 billion question: is Europe finally building strategic capital — or still thinking too small?

Scaleup Europe Fund targets €5bn, but HealthTech Alpha data shows Europe’s real gap is Series C–E growth capital

Read insight
Big Tech’s role in healthcare through AI, cloud infrastructure, consumer health data and digital health partnerships
Point of ViewArtificial Intelligence

Big Tech is no longer experimenting at the edges of healthcare. Microsoft, Amazon, Google, Apple, NVIDIA and Meta are becoming part of healthcare’s infrastructure, AI, data, consumer access and venture partnership layer.

Big Tech is becoming part of the operating system of modern healthcare. From AI and cloud infrastructure to wearables, pharmacy, clinical workflow and digital health partnerships, companies such as Microsoft, Amazon, Google, Apple and NVIDIA are reshaping how healthcare is delivered, analyzed and accessed.

Read insight
Isomorphic Labs $2.1 billion
FundingMerger & Acquisition

The $2.1bn wager on machine-made medicine: why Isomorphic Labs may redraw the economics of drug discovery

Isomorphic Labs' $2.1B Series B signals a major shift in AI drug discovery. Explore what the funding means for pharma, investors, AI biology and the future of medicine.

Read insight